Breaks Categories: News

ThursdayNov 16, 2017 9:13 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Presenting at Cannabis-Based Science & Medicine Conference

InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) this morning said that it will be presenting twice at the Biopharma Forum on 'Cannabis-Based Science & Medicine' conference. The company will present on Thursday, November 30 and Friday, December 1 at the conference taking place in Denver, CO. The company’s chief scientific officer, Dr. Sazzad Hossain, will be presenting a lecture titled "Epidermolysis to Glaucoma - Identifying Pathology Candidates for Cannabis-Based Treatments." Among other areas of interest, the lecture will shine a light on InMed’s methods of identifying disease targets for cannabinoid compound treatments. To view the full press release, visit http://cnw.fm/9nvGz About…

Continue Reading

WednesdayNov 15, 2017 9:20 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Adds Key Individuals to Board and Executive Team

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) today announced that it has added Mr. Rick Fitzgerald to the Board of Directors and Dr. Michael Bumby to the executive team as Chief Financial Officer. Fitzgerald brings a wealth of strategic marketing and senior leadership experience in the alcoholic beverage and tobacco industries while Bumby adds extensive financial, international and capital markets experience. Paul Lucas, Chair of ABcann’s board of directors, stated, “We are pleased to welcome two outstanding individuals to ABcann and believe their domestic and global business experience will be a significant asset to the Company.” To view the full…

Continue Reading

MondayNov 13, 2017 3:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Covered in November ‘Let’s Toke Business’ Report Alongside Canopy Growth (TSX: WEED)

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has been featured in the November issue of ‘Let’s Toke Business.’ The report draws similarities between Lexaria and Canopy Growth (TSX: WEED), as both companies have had major breakouts on the stock market recently. The ability of Lexaria’s technology to expand into other markets was mentioned in the report, as well the possibility that non-cannabis applications could demonstrate an even greater potential. On November 9, Lexaria announced that it filed a new patent application with the U.S. Patent and Trademark…

Continue Reading

ThursdayNov 09, 2017 10:43 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Filing of New Patent Application with USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Existing products occupying this space include Viagra™ (sildenafil) and Cialis™ (tadalafil). Per the update, a common complaint regarding existing PDE5 inhibitors relates to the slow-acting nature of the substances. Lexaria believes that its patented DehydraTECH™ technology, building on existing research with cannabinoid delivery, will…

Continue Reading

ThursdayNov 02, 2017 12:44 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Acquisition of 100% Ownership Interest in Poviva Tea, LLC

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has acquired 100 percent ownership interest in its majority owned subsidiary, Poviva Tea, LLC. Lexaria previously owned 51 percent interest in Poviva Tea. “This acquisition strengthens Lexaria's intellectual property positioning and we reaffirm our commitment to the ViPova Tea product lines,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria thanks the founders of Poviva Tea, LLC for their assistance and vision in this transaction.” Per the update, compensation related…

Continue Reading

WednesdayNov 01, 2017 10:10 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Receives Extensive Patent Allowance from USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, announced late yesterday that it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) related to the use of its innovative DehydraTECH™ technology as a delivery platform for the full list of active pharmacological ingredients requested, including all cannabinoids, fat-soluble vitamins, nonsteroidal anti-inflammatory pain medications (“NSAIDs”) and nicotine. The company expects formal patent issuance within three to four months, with provided protections extending through 2035 or later. “This wide-ranging patent allowance from the USPTO exceeds our expectations,” Chris Bunka, chief executive…

Continue Reading

WednesdayOct 25, 2017 11:25 am

CannabisNewsBreaks – FinCanna Capital Corp. and Astar Minerals Ltd. (TSX.V: TAR) Announce Profit Sharing Agreement with Cultivation Technologies, Inc.

FinCanna Capital Corp., a royalty company for licensed medical cannabis, and Astar Minerals Ltd. (TSX.V: TAR) this morning announced that FinCanna will share 50 percent of the profits from Cultivation Technologies’ (“CTI”) interim medical cannabis extraction facility operating in Coachella, California. The new arrangement, which commenced on October 1, 2017, is expected to provide FinCanna with a source of monthly revenue before the construction of CTI’s Coachella campus is completed as planned. As noted in a news release issued on September 12, 2017, this interim medical cannabis extraction facility on the Coachella premises was established in accordance with CTI’s Conditional…

Continue Reading

TuesdayOct 24, 2017 9:41 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Highlights Positive Pre-Clinical Data Related to Biosynthesis Platform

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced results from a study co-sponsored by InMed and the University of British Columbia. Notably, this study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye resulting in enhanced drug uptake via the cornea and lens. “Importantly, this study offers further validation of InMed's capabilities in moving the science of cannabinoid pharmaceuticals forward,” Eric A. Adams, president and CEO of InMed, stated in the news release. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned…

Continue Reading

TuesdayOct 17, 2017 9:32 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Paul Lucas as New Board Chair

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the…

Continue Reading

TuesdayOct 10, 2017 9:51 am

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Addition of Dr. Mauro Maccarrone to Scientific Advisory Board

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the addition of Dr. Mauro Maccarrone to its scientific advisory board. Maccarrone is professor and chair of biochemistry and molecular biology at Campus Bio-Medico, University of Rome. He also serves as director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome. “InMed is dedicated to developing industry-leading products in diseases with high unmet medical needs. One key element in drug development is to ensure that we are working with leading scientists in the field who can contribute their…

Continue Reading